C-1101 demonstrates immunomodulatory activity in vitro and corresponding reductions in neuropathic pain in vivo in preclinical models

BURLINGTON, MA — March 30, 2026 — Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced the presentation of preclinical data supporting its lead investigational therapy, C-1101, at the Orthopaedic Research Society (ORS) 2026 Annual Meeting in Charlotte, NC. The data were presented in a poster session highlighting translational research on immunomodulation and neuropathic pain.

The studies evaluated C-1101’s immunomodulatory activity across multiple translational models. Results demonstrated anti-inflammatory effects of C-1101 in activated human immune cells. Gene expression analyses of spinal disc and dorsal root ganglion cells treated with C-1101 indicated modulation of key inflammatory pathways and activation of growth related pathways. In a rodent model of peripheral neuropathy, treatment with C-1101 reduced pain sensitivity.

The work was presented by Dr. Lynn Pezzanite, DVM, MS, PhD, Diplomate and Fellow American College of Veterinary Surgeons (ACVS), Assistant Professor of Cellular and Molecular Biology in the Department of Clinical Sciences and College of Veterinary Medicine and Biomedical Sciences at Colorado State University. Dr. Pezzanite was selected as a recipient of the 2026 ORS/OREF Travel Grant in Orthopaedic Research Translation for her poster. Studies to support the submitted abstract were performed in the Translational Medicine Institute at Colorado State University in conjunction with Dr. Steven Dow, DVM, PhD, Diplomate American College of Veterinary Internal Medicine and Director of the Immunotherapy Research Laboratory.

Chronic sciatica or chronic lumbosacral radiculopathy (LSR) affects millions of patients and currently has no FDA-approved disease-modifying therapies. Existing interventions often provide temporary relief without directly addressing the underlying biology of nerve injury and persistent inflammation. “Translational studies like this are important to eludicate the mechanism of action of new therapeutics such as orthobiologics for musculoskeletal conditions that have been historically difficult to treat.” said Dr. Lynn Pezzanite.

“The data presented at ORS reinforce our belief that C-1101 has the potential to address the underlying drivers of chronic nerve-related pain,” said Andrew Hall, Consano Bio Chief Executive Officer. “These data provide important scientific support as we advance C-1101 through clinical development toward potentially becoming the first FDA-approved, disease-modifying therapy for chronic LSR.”

C-1101 is currently being evaluated in a Phase 1 clinical trial (NCT07264270) designed to assess safety, tolerability, and exploratory clinical endpoints following epidural administration in patients with chronic LSR.

About Chronic Lumbosacral Radiculopathy (LSR)
Chronic painful LSR, or sciatica, is a chronic lower back pain condition caused by damage or irritation of spinal nerve roots, leading to radiating pain, numbness, and weakness from the spine into the leg. There are no FDA-approved pharmaceutical treatments for chronic sciatica despite its prevalence and widespread societal and economic impact.

About C-1101
C-1101 is Consano Bio’s lead investigational clinical candidate and the first pharmaceutical therapy of its kind: a novel, platelet-derived multi-protein biologic therapeutic. It is designed to treat LSR, or chronic sciatica, by modulating inflammation and stimulating and enhancing cellular repair at the site of injury. The product contains consistent concentrations of cytokines, growth factors, and matrix proteins to help trigger the body’s natural healing response. Delivered via an epidural injection, C-1101 provides supraphysiologic concentrations of these proteins directly to the site of nerve injury.

About Consano Bio
Consano Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of painful and debilitating orthopedic conditions through a new class of multi-protein biologic therapeutics. Founded in 2023 and headquartered in the Greater Boston area. For more information, visit www.consanobio.com.

Contacts
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com